Ships from British Columbia, Canada|Canadian Orders Ship Domestically, No Border Crossing|International Shipping Available|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|Canadian Orders Ship Domestically, No Border Crossing|International Shipping Available|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|Canadian Orders Ship Domestically, No Border Crossing|International Shipping Available|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|Canadian Orders Ship Domestically, No Border Crossing|International Shipping Available|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|
All Comparisons

BPC-157 vs Sermorelin

Research material comparison: purity standards, available formats, molecular data, batch COA documentation, and regulatory status. For in vitro research use only.

BPC-157: CSermorelin: C
AttributeBPC-157Sermorelin
CategoryHealing & RecoveryGrowth Hormone Secretagogue
Evidence RatingC — Phase I–II Clinical TrialsC — Phase I–II Clinical Trials
Clinical StatusResearch-only / No approved human indication. Phase I oral safety trial completed; Phase II UC trial underway.Previously FDA-approved (Geref, discontinued); now used off-label via compounding
MechanismBPC-157 acts through multiple overlapping pathways. It promotes angiogenesis by upregulating VEGFR2 and VEGF expression, and activates nitric oxide synthesis via the Src kinase-caveolin-1 pathway and Akt-eNOS axis. It engages ERK1/2 signaling, activating c-Fos, c-Jun, and EGR-1 transcription factors...Sermorelin binds to GHRH receptors (GHRHR) on somatotroph cells in the anterior pituitary gland, stimulating both transcription of the HGH gene and pulsatile release of endogenous growth hormone. The released HGH increases protein synthesis, fat breakdown (lipolysis), and tissue repair across multip...
Half-Life~15 min IV (animal data); oral activity persists 24+ hours~10–20 minutes
BioavailabilityIM: 15-19% (rats), 45-51% (dogs); resistant to stomach acid degradation—
Molecular Weight~1419.5 g/mol~3357.9 g/mol
WADA StatusProhibitedProhibited
Research Half-Life~15 min IV (animal data); oral activity persists 24+ hours~10–20 minutes
Key Use Cases
  • Injury Recovery
  • Gut Health
  • Anti-Aging
  • Body Composition
  • Sleep
Safety Concerns
  • No completed randomized controlled human clinical trials for safety assessment
  • Preclinical safety studies across multiple species found no toxic or lethal dose thresholds at ranges from 6 mcg/kg to 20 mg/kg; LD1 not achieved; no teratogenic, genotoxic, or anaphylactic effects in necropsy/histopathology
  • FDA previously classified BPC-157 as Category 2 (significant safety concerns); removed from Category 2 on April 15, 2026. PCAC review pending July 2026 to determine compounding eligibility. FDA noted insufficient human safety data and potential immunogenicity risks.
  • Generally well-tolerated in clinical studies; safety data from published trials supports good tolerability profile
  • Common: injection site reactions (redness, swelling, mild pain — typically resolve within days)
  • Systemic: headaches, nausea, dizziness, facial flushing, drowsiness (mild, transient, usually in initial weeks as the body adjusts)
Contraindications
  • Pregnancy and breastfeeding (no safety data)
  • Active cancer or history of cancer (theoretical concern due to potent angiogenesis promotion; mechanistic overlap with tumor vascularization)
  • Individuals on anticoagulants (BPC-157 affects clotting and vessel constriction resolution)
  • Autoimmune conditions (immunogenicity risk noted by FDA)
  • Active malignancy or active cancer (GH promotes cell proliferation)
  • Pregnancy and breastfeeding
  • Pituitary disorders or prior pituitary surgery
  • Uncontrolled diabetes, severe sleep apnea, or untreated hypertension
Regulatory (US)Not FDA-approved. Removed from Category 2 on April 15, 2026 after HHS Secretary Kennedy directed withdrawal of nominations. PCAC review scheduled July 23-24, 2026 to determine compounding eligibility. Previously prohibited from compounding under Category 2 since September 2023. WADA-banned.Previously FDA-approved (Geref) for pediatric GH deficiency; voluntarily discontinued by manufacturer for commercial reasons. FDA confirmed in 2013 it was not withdrawn for safety. Available via compounding pharmacies. WADA-banned.

Research Material Specifications

Catalog specifications for the corresponding research materials, including batch documentation coverage.

SpecificationBPC-157Sermorelin
Purity Standard≥98%≥98%
CAS Number137525-51-086168-78-7
Molecular FormulaC₆₂H₉₈N₁₆O₂₂C₁₄₉H₂₄₆N₄₄O₄₂S
Available Formats5mg, 10mg, 10mg5mg
Batch COAs Published——
Stock StatusIn stockOut of stock

Availability at Volta Peptides

BPC-157 5mg

≥98% purity · HPLC verified · In stock

$24.57

Sermorelin 5mg

≥98% purity · HPLC verified · Restocking

$35.41

Research Disclaimer: This comparison is provided for educational purposes only. All products are sold exclusively for in vitro research use. The information presented is based on published preclinical and clinical research and does not constitute medical advice. Consult a qualified healthcare professional before making any decisions regarding peptide use.

Explore More
Comparisons

Compare any two peptides side-by-side or browse our curated popular matchups.

All ComparisonsBrowse Catalog

Your Cart

Your cart is empty

Browse our catalog to add research compounds.